Vorinostat (SAHA) and breast cancer: an overview
A Wawruszak, L Borkiewicz, E Okon, W Kukula-Koch… - Cancers, 2021 - mdpi.com
Simple Summary Breast cancer (BC) is the most frequent malignancy diagnosed in 2020
worldwide. Despite significant advances in BC therapy, its pathogenesis is still not fully …
worldwide. Despite significant advances in BC therapy, its pathogenesis is still not fully …
Differential molecular mechanistic behavior of HDACs in cancer progression
Genetic aberration including mutation in oncogenes and tumor suppressor genes transforms
normal cells into tumor cells. Epigenetic modifications work concertedly with genetic factors …
normal cells into tumor cells. Epigenetic modifications work concertedly with genetic factors …
[HTML][HTML] Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors?
G Natale, E Fini, PF Calabrò, M Carli, M Scarselli… - Cancer Letters, 2023 - Elsevier
Beyond its use as an antiepileptic drug, over time valproate has been increasingly used for
several other therapeutic applications. Among these, the antineoplastic effects of valproate …
several other therapeutic applications. Among these, the antineoplastic effects of valproate …
HSP70s in breast cancer: promoters of tumorigenesis and potential targets/tools for therapy
AE Kabakov, VL Gabai - Cells, 2021 - mdpi.com
The high frequency of breast cancer worldwide and the high mortality among women with
this malignancy are a serious challenge for modern medicine. A deeper understanding of …
this malignancy are a serious challenge for modern medicine. A deeper understanding of …
Epigenetic Regulation in Breast Cancer: Insights on Epidrugs
A Kim, K Mo, H Kwon, S Choe, M Park, W Kwak… - Epigenomes, 2023 - mdpi.com
Breast cancer remains a common cause of cancer-related death in women. Therefore,
further studies are necessary for the comprehension of breast cancer and the revolution of …
further studies are necessary for the comprehension of breast cancer and the revolution of …
[HTML][HTML] Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer
SD Pramanik, A Kumar Halder, U Mukherjee… - Frontiers in …, 2022 - frontiersin.org
Histone deacetylases (HDAC) are enzymes that play a role in chromatin remodeling and
epigenetics. They belong to a specific category of enzymes that eliminate the acetyl part of …
epigenetics. They belong to a specific category of enzymes that eliminate the acetyl part of …
Control of redox homeostasis by short-chain fatty acids: implications for the prevention and treatment of breast cancer
C González-Bosch, PA Zunszain, GE Mann - Pathogens, 2023 - mdpi.com
Breast cancer is the leading cause of death among women worldwide, and certain subtypes
are highly aggressive and drug resistant. As oxidative stress is linked to the onset and …
are highly aggressive and drug resistant. As oxidative stress is linked to the onset and …
Valproic acid inhibits cell growth in both MCF-7 and MDA-MB231 cells by triggering different responses in a cell type-specific manner
F Giordano, A Paolì, M Forastiero, S Marsico… - Journal of Translational …, 2023 - Springer
Background Breast cancer is the second leading cause of death among women after lung
cancer. Despite the improvement in prevention and in therapy, breast cancer still remains a …
cancer. Despite the improvement in prevention and in therapy, breast cancer still remains a …
Assessment of pharmacological interactions between SIRT2 inhibitor AGK2 and paclitaxel in different molecular subtypes of breast cancer cells
A Wawruszak, J Luszczki, A Czerwonka, E Okon… - Cells, 2022 - mdpi.com
Breast carcinoma (BC) is the most commonly diagnosed type of cancer in women in the
world. Although the advances in the treatment of BC patients are significant, numerous side …
world. Although the advances in the treatment of BC patients are significant, numerous side …
Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin
A Granit, K Mishra, D Barasch… - Frontiers in Cell and …, 2022 - frontiersin.org
Cisplatin is an effective chemotherapeutic agent for treating triple negative breast cancer
(TNBC). Nevertheless, cisplatin-resistance might develop during the course of treatment …
(TNBC). Nevertheless, cisplatin-resistance might develop during the course of treatment …